Company Encyclopedia
View More
name
RemeGen
688331.SH
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of various cancers. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People’s Republic of China.
1.585 T
688331.SHMarket value -Rank by Market Cap -/-

Financial Score

07/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking16/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-40.42%E
    • Profit Margin-42.54%E
    • Gross Margin84.63%A
  • Growth ScoreB
    • Revenue YoY46.34%A
    • Net Profit YoY38.94%B
    • Total Assets YoY4.63%C
    • Net Assets YoY-2.05%D
  • Cash ScoreC
    • Cash Flow Margin-235.09%D
    • OCF YoY46.34%A
  • Operating ScoreC
    • Turnover0.38C
  • Debt ScoreD
    • Gearing Ratio61.18%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Asian Market Value Picks Featuring 3 Stocks Trading Below Estimated Worth

    Asian markets face AI valuation concerns, leading investors to seek undervalued stocks. Notable picks include Samyang Foods, China Ruyi Holdings, and RemeGen, all trading below estimated fair values. Samyang Foods shows strong growth potential with U.S. collaborations. China Ruyi Holdings is undervalued despite shareholder dilution, with a forecasted price increase. RemeGen reports revenue growth and reduced net loss, indicating future financial strength. Simply Wall St offers tools for investment analysis and portfolio management.

    Simplywall·
    HK
    09995
    -11.49%
    SH
    688331
    -10.77%
    HK
    00136
    -2.45%
    Simplywall·
    HK
    09995
    -11.49%
    SH
    688331
    -10.77%
    HK
    00136
    -2.45%

    RemeGen Co., Ltd. Announces 2025 Third Extraordinary General Meeting

    RemeGen Co., Ltd. has announced its 2025 third extraordinary general meeting (EGM) set for December 2, 2025. The meeting will discuss resolutions on related party transactions for 2026-2028 and amendments to governance policies, potentially affecting the company's operations and strategy. The latest analyst rating for RemeGen's stock (HK:9995) is a Sell, with a price target of HK$86.00. RemeGen operates in the biopharmaceutical sector and is listed on the Hong Kong Stock Exchange, with a current market cap of HK$49.78B.

    Tip Ranks·
    SH
    688331
    -10.77%
    HK
    09995
    -11.49%
    Tip Ranks·
    SH
    688331
    -10.77%
    HK
    09995
    -11.49%

    Morgan Stanley: Raises RemeGen's target price to HKD 77 and upgrades rating to Neutral

    JP Morgan released a research report stating that it has lowered the product revenue forecasts for RemeGen (09995) for 2025 and 2026 to reflect the latest performance, while raising the licensed revenue forecast. With the improvement in profit margins and reduction in operating expenses, the bank expects the net loss for 2025 and 2026 to narrow, thus raising the target price for H shares from HKD 73 to HKD 77, with the rating upgraded to Neutral; the target price for A shares is raised from RMB 86 to RMB 92, maintaining a "Neutral" rating. The bank noted that RemeGen's performance in the third quarter was mixed, with product revenue lower than expected, but profit margins and operating expense control were better than expected, reflecting the company's ongoing cost optimization. Notably, after signing the RC18 licensing agreement with VorBio in June, the company's R&D expenses decreased by 30% year-on-year and 24% quarter-on-quarter; administrative expenses also fell by 23%, continuing the positive momentum from previous quarters

    Zhitong·
    SH
    688331
    -10.77%
    HK
    09995
    -11.49%
    Zhitong·
    SH
    688331
    -10.77%
    HK
    09995
    -11.49%

    RemeGen’s Reduced Losses and Telitacicept Results Could Be a Game Changer for RemeGen (SEHK:9995)

    RemeGen (SEHK:9995) reported a sales increase to CNY 1,719.83 million and reduced its net loss to CNY 550.7 million for the nine months ending September 30, 2025. Promising results from a Phase 3 study of telitacicept in generalized myasthenia gravis could enhance RemeGen's investment outlook. Despite operational improvements, concerns about high operating losses and share valuations persist. Investor sentiment is cautiously optimistic, with shares potentially undervalued by 11%. A consensus fair value estimate stands at HK$104.04, reflecting varied investor perspectives on the company's future profitability and pipeline execution.

    Simplywall·
    HK
    09995
    -11.49%
    SH
    688331
    -10.77%
    Simplywall·
    HK
    09995
    -11.49%
    SH
    688331
    -10.77%

    Jiangyin International: Raises RemeGen target price to HKD 112, maintains "Buy" rating

    Jiangyin International raised the target price of RemeGen to HKD 112, maintaining a "Buy" rating. The company's third-quarter revenue increased by 33% year-on-year to CNY 620 million, with sales revenue of TaiTasiPu at CNY 380 million and sales revenue of WeiDiXiTuo at CNY 240 million. Management is confident in achieving the annual product sales revenue growth target of over 30%, and expects to confirm the upfront payment revenue from the BD licensing transactions of TaiTasiPu and RC28 in the fourth quarter

    Zhitong·
    SH
    688331
    -10.77%
    HK
    09995
    -11.49%
    Zhitong·
    SH
    688331
    -10.77%
    HK
    09995
    -11.49%
    Posts
    View More
    © 2025 Longbridge｜Disclaimer